Venous Thromboembolism Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

Veröffentlicht von: precision business insights
Veröffentlicht am: 28.03.2018 08:33
Rubrik: Gesundheit & Medizin


(Presseportal openBroadcast) - Venous Thromboembolism Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

Pressekontakt:

Venous Thromboembolism Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

Venous Thromboembolism Disease Pipeline Drugs Assessment

Overview:
Venous Thromboembolismis a disease caused by clotting of blood in blood vessel which leads to restriction of blood flow within the circulatory system. Venous thromboembolism is classified into pulmonary embolism and deep vein thrombosis. Deep vein thrombosis is mainly occurred due to the clotting of the blood in the deep vein (commonly in the leg). The formed DVT clot breaks off and flows to the lungs known as pulmonary embolism which is a severe complication of deep vein thrombosis (DVT). Venous thromboembolism commonly occurs in aged persons with more than 60 years.
The symptoms associated with the venous thromboembolism include dilated blood veins in legs and chest, edema, fever, tachycardia, and dyspnea. Lower extremities are the most common site for DVT, but other locations affected include the mesenteric, upper extremities, pelvic veins, and cerebral vein. Venous Thromboembolism is treated by blood thinners, clot-busting drugs and surgery.

A sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/venous-thromboembolism-disease-pipeline-drugs-assessment/#ulp-4H8Z4LpNMLEuOnnx

Segmentation:
By Trial Phase, Venous Thromboembolism pipeline drugs are segmented as:
• Preclinical Trials
• Phase 1
• Phase 2
• Phase 3
• Phase 4
By Company, Venous Thromboembolism pipeline drugs are segmented as:
• Pfizer
• Bristol-Myers Squibb
• Bayer
• Janssen Research & Development, LLC
• Daiichi Sankyo, Inc
• BoehringerIngelheim
• GlaxoSmithKline
• Others
By Drugs, Venous Thromboembolism pipeline drugs are segmented as:
• Rivaroxaban
• Apixaban
• Edoxaban
• Tinzaparin
• Betrixaban
• Enoxaparin
• Others
By Type of Condition, Venous Thromboembolism pipeline drugs are segmented as:
• Deep vein thrombosis
• pulmonary embolism
By Route of Administration, Venous Thromboembolismpipeline drugs are segmented as:
• Oral
• Parenteral

To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/venous-thromboembolism-disease-pipeline-drugs-assessment/#ulp-c654SbFYO64MsOhu


Space Analysis:
• In March 2017, Daiichi Sankyo, Inc. commenced a phase 3, open-label, randomized, multi-center, controlled trial to evaluate the pharmacokinetics and pharmacodynamics of edoxaban and to compare the efficacy and safety of edoxaban with standard of care anticoagulant therapy in pediatric subjects from birth to less than 18 years of age with confirmed venous thromboembolism
• In November 2015, Pfizer in collaboration with Bristol-Myers Squibb commenced a phase 4 randomized, open label, active controlled, safety and descriptive efficacy study in pediatric subjects requiring anticoagulation of apixaban for the treatment of venous thromboembolism

Report Description:
Venous Thromboembolism Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Venous Thromboembolism treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Venous Thromboembolism disease pipeline drugs development. This report studies the dynamics of the Venous Thromboembolism Disease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Venous Thromboembolism disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.
Need more information about this report @
https://www.precisionbusinessinsights.com/market-reports/venous-thromboembolism-disease-pipeline-drugs-assessment/#ulp-14mlyhjMGhVjZqa3

Key Features of the Report:
• Provides the information related to universities and research institutes working in the therapeutics development
• Report comprehensively covers the all active and discontinued studies
• Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
• Presents the prominent targets for drug development in each stage of clinical trial
• Provides the in-depth analysis on the each drug candidates in the clinical trial phases


Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/venous-thromboembolism-disease-pipeline-drugs-assessment/
About Precision Business Insights

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

Contact to Precision Business Insights,

Kemp House,
152 – 160 City Road,
London EC1V 2NX

Email: sales@precisionbusinessinsights.com

Toll Free (US): +1-866-598-1553
Website @ https://www.precisionbusinessinsights.com


Bitte beachten Sie, dass für den Inhalt der hier veröffentlichten Meldung nicht openBroadcast verantwortlich ist, sondern der Verfasser der jeweiligen Meldung selbst. AGB | Haftungsausschluss.